Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
Protocol # 22-192

Status

Recruiting

Description

Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory B-Cell NHL or CLL

Condition

  • Follicular B-cell Non-Hodgkin's Lymphoma
  • Mantle Cell Lymphoma Recurrent
  • Mantle Cell Lymphoma Refractory
  • Small Lymphocytic Lymphoma, Relapsed
  • Waldenstrom's Macroglobulinemia Recurrent
  • Waldenstrom's Macroglobulinemia Refractory
  • Chronic Lymphoid Leukemia in Relapse
  • B-cell Lymphoma Refractory

Interventions

  • MB-106

Phase

Phase 1/Phase 2

Study Type

Interventional

Further Study Details

Primary Outcome:

  • Phase 1: Primary objective
  • Phase 1: Primary objective
  • Phase 2: Primary objective

Secondary Outcome:

  • Phase 1: Secondary objective
  • Phase 1: Secondary objective
  • Phase 1: Secondary objective
  • Phase 2: Secondary objective
  • Phase 2: Secondary objective
  • Phase 2: Secondary objective

Enrollment

287

Study Start Date

May 24, 2022

Eligibility

  • Gender:     All
  • Minimum age:     18 Years
  • Maximum age:     N/A
  • Healthy volunteers:     No

Sponsors

Mustang Bio

Source

Mustang Bio

Official title

A Phase 1/2, Open Label, Multicenter Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory CD20+ B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Clinicaltrials.gov Identifier

NCT05360238

     

Source: Clinicaltrials.gov. Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.